Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for ...

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

June 2 (Reuters) - Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

The U.S. Food and Drug Administration on Friday proposed to reduce animal studies conducted to assess safety in the development of certain cancer medications, marking the agency’s latest effort to ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI ...

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient ...

In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 ...

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed ...

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvalsAppointment strengthens confidence in clinical readiness and ...